Structural biology of neurotransmitter ion channels
神经递质离子通道的结构生物学
基本信息
- 批准号:8218012
- 负责人:
- 金额:$ 27.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-02-01 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAgonistAlzheimer&aposs DiseaseAnestheticsAnticonvulsantsBasic ScienceBindingBinding SitesBiological AssayBiological ProcessButyric AcidsCaenorhabditis elegansCellsChemicalsCommunicationComplexCrystallizationDetergentsDevelopmentDiseaseEnvironmentEpilepsyEventFamilyFoundationsGated Ion ChannelGlutamatesGlycineGlycine ReceptorsHeterogeneityHumanInjuryInsectaIntegral Membrane ProteinInvertebratesIon ChannelIon Channel GatingIon Channel ProteinLigand BindingLigandsLightLinkLipidsMammalian CellMapsMeasurementMembraneMembrane ProteinsMethodsMicellesMolecularMolecular MachinesMolecular Mechanisms of ActionMutagenesisNervous system structureNeuronsNeurotransmittersNicotineP2X-receptorParkinson DiseasePeripheral Nervous SystemPhasePlayPoriferaProductionPublishingRefractoryResolutionRoleScreening procedureSerotoninSignal TransductionSiteSite-Directed MutagenesisSourceStructureTestingTherapeutic AgentsWorkdesigndrug discoveryextracellularfallsglutamate-gated chloride channelglycosylationinsightnovelnovel therapeuticsoverexpressionreceptorreceptor bindingsedativestructural biology
项目摘要
DESCRIPTION (provided by applicant): The normal development and function of the human nervous system is critically dependent upon the function of neurotransmitter- or ligand-gated ion channels, molecular machines which facilitate the communication between one nerve cell and another. Equally important, these ion channels are the targets of many therapeutic agents, from sedatives and anesthetics to anticonvulsants, and they are implicated or associated with a broad range of devastating diseases including Alzheimer's and Parkinson's diseases as well as epilepsy. Two major and important families of neurotransmitter-gated ion channels are the ATP- sensitive P2X receptors and the pentameric Cys-loop receptors, the latter of which subsumes a super family of receptors that includes those for 3-amino butyric acid (GABA), glycine, serotonin and, in invertebrates, for glutamate. Unfortunately there are no high resolution, atomic views of any of these receptors in complexes with their cognate neurotransmitters or agonists. Furthermore, in the case of Cys- loop receptors, there is not yet even a high resolution structure of a eukaryotic receptor or a published method for production of receptor suitable for high resolution structural studies. Without this information, we are unable to understand how these important neurotransmitter-gated ion channels 'work' and, most significantly, we do not have molecular maps of the binding sites for neurotransmitters on the one hand, and molecules that inhibit neurotransmitter activity, i.e. antagonists, on the other hand. Because neurotransmitter-gated ion channels are multimeric integral membrane proteins they are particularly difficult to isolate and crystallize. The aim of the work proposed in this application is to develop new methods to screen and prepare neurotransmitter-gated ion channels for crystallographic studies, to design and implement new crystallization screening conditions, and to apply these methods to study P2X and Cys-loop receptors. Most specifically, we aim to solve high resolution x-ray crystal structures of P2X and Cys-loop receptors bound to their cognate neurotransmitter and to competitive antagonists, to test the veracity of the mapped sites by site-directed mutagenesis and ligand-binding assays, and to develop molecular mechanisms for the action of agonists and antagonists in these receptors. Taken together, our studies will provide the first atomic resolution views of these crucial receptors in their active and inhibited states, thus not only providing fundamental insight into their biological function, but also laying the foundation for the rational design of new therapeutic agents.
PUBLIC HEALTH RELEVANCE: Neurotransmitter-gated ion channel proteins are eukaryotic, multimeric integral membrane proteins that have proven especially challenging to isolate and crystallize. The aim of the work proposed in this application is to develop new methods for the screening, expression and crystallization of these crucial molecular machines and to apply the methods to two classes of crucial neurotransmitter-gated ion channels, ATP-gated P2X receptors and Cys-loop receptors. Completion of the proposed work will provide new insights into molecular mechanism and will yield atomic-resolution 'blueprints' of neurotransmitter and competitive antagonist binding sites, information which in turn will spur the development of novel therapeutic agents.
描述(申请人提供):人类神经系统的正常发育和功能严重依赖于神经递质或配体门控离子通道的功能,这些离子通道是促进一个神经细胞和另一个神经细胞之间通讯的分子机器。同样重要的是,这些离子通道是许多治疗药物的靶标,从镇静剂、麻醉剂到抗惊厥药物,它们涉及或与包括阿尔茨海默氏症、帕金森氏症以及癫痫在内的一系列破坏性疾病有关。神经递质门控离子通道的两个主要和重要的家族是ATP敏感的P2X受体和五聚体Cys-loop受体,后者包括一个超级受体家族,包括3-氨基丁酸(GABA)、甘氨酸、5-羟色胺和无脊椎动物的谷氨酸受体。不幸的是,在与其同源神经递质或激动剂的复合体中,这些受体中的任何一个都没有高分辨率的原子视图。此外,在Cys-loop受体的情况下,甚至还没有真核受体的高分辨率结构,也没有公开的方法来生产适合于高分辨率结构研究的受体。没有这些信息,我们就无法理解这些重要的神经递质门控离子通道是如何工作的,最重要的是,我们一方面没有神经递质的结合位点的分子图谱,另一方面也没有抑制神经递质活性的分子,即拮抗剂。由于神经递质门控离子通道是多聚体完整膜蛋白,因此分离和结晶特别困难。本申请工作的目的是开发新的方法来筛选和制备用于结晶学研究的神经递质门控离子通道,设计和实施新的结晶筛选条件,并将这些方法应用于P2X和Cys-loop受体的研究。更具体地说,我们的目标是解决P2X和Cys-loop受体与其同源神经递质和竞争性拮抗剂结合的高分辨率X射线晶体结构,通过定点突变和配体结合分析来检验定位位点的准确性,并开发这些受体中激动剂和拮抗剂的作用分子机制。综上所述,我们的研究将提供这些关键受体在激活和抑制状态下的第一个原子分辨率视图,从而不仅提供对它们生物学功能的基本见解,而且为合理设计新的治疗药物奠定基础。
与公共健康相关:神经递质门控离子通道蛋白是真核多聚体完整膜蛋白,已被证明对分离和结晶特别具有挑战性。本申请工作的目的是开发新的方法来筛选、表达和结晶这些关键的分子机制,并将这些方法应用于两类关键的神经递质门控离子通道,即ATP门控的P2X受体和Cys-loop受体。拟议工作的完成将为分子机制提供新的见解,并将产生神经递质和竞争性拮抗剂结合位点的原子分辨“蓝图”,这些信息反过来将刺激新治疗药物的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James E Gouaux其他文献
James E Gouaux的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James E Gouaux', 18)}}的其他基金
Structural biology of neurotransmitter ion channels
神经递质离子通道的结构生物学
- 批准号:
9896831 - 财政年份:2012
- 资助金额:
$ 27.72万 - 项目类别:
Structural biology of neurotransmitter ion channels
神经递质离子通道的结构生物学
- 批准号:
8608553 - 财政年份:2012
- 资助金额:
$ 27.72万 - 项目类别:
Structural biology of neurotransmitter ion channels
神经递质离子通道的结构生物学
- 批准号:
8413048 - 财政年份:2012
- 资助金额:
$ 27.72万 - 项目类别:
STRUCTURE AND FUNCTION OF RECEPTORS AND TRANSPORTERS AT CHEMICAL SYNAPSES
化学突触受体和转运蛋白的结构和功能
- 批准号:
8361620 - 财政年份:2011
- 资助金额:
$ 27.72万 - 项目类别:
STRUCTURE AND FUNCTION OF RECEPTORS AND TRANSPORTERS AT CHEMICAL SYNAPSES
化学突触受体和转运蛋白的结构和功能
- 批准号:
8169236 - 财政年份:2010
- 资助金额:
$ 27.72万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF TRANSPORTERS AND RECEPTORS
转运体和受体的晶体学研究
- 批准号:
7954392 - 财政年份:2009
- 资助金额:
$ 27.72万 - 项目类别:
MOLECULAR FUNCTION OF RECEPTORS AND TRANSPORTERS AT CHEMICAL SYNAPSES
化学突触受体和转运蛋白的分子功能
- 批准号:
7955124 - 财政年份:2009
- 资助金额:
$ 27.72万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF TRANSPORTERS AND RECEPTORS
转运体和受体的晶体学研究
- 批准号:
7722058 - 财政年份:2008
- 资助金额:
$ 27.72万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF TRANSPORTERS AND RECEPTORS
转运体和受体的晶体学研究
- 批准号:
7598319 - 财政年份:2007
- 资助金额:
$ 27.72万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 27.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 27.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 27.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




